51
|
Abstract
Enterohemorrhagic Escherichia coli (EHEC) is a highly pathogenic bacterial strain capable of causing watery or bloody diarrhea, the latter termed hemorrhagic colitis, and hemolytic-uremic syndrome (HUS). HUS is defined as the simultaneous development of non-immune hemolytic anemia, thrombocytopenia, and acute renal failure. The mechanism by which EHEC bacteria colonize and cause severe colitis, followed by renal failure with activated blood cells, as well as neurological symptoms, involves the interaction of bacterial virulence factors and specific pathogen-associated molecular patterns with host cells as well as the host response. The innate immune host response comprises the release of antimicrobial peptides as well as cytokines and chemokines in addition to activation and/or injury to leukocytes, platelets, and erythrocytes and activation of the complement system. Some of the bacterial interactions with the host may be protective in nature, but, when excessive, contribute to extensive tissue injury, inflammation, and thrombosis, effects that may worsen the clinical outcome of EHEC infection. This article describes aspects of the host response occurring during EHEC infection and their effects on specific organs.
Collapse
|
52
|
Swieringa F, Baaten CCFMJ, Verdoold R, Mastenbroek TG, Rijnveld N, van der Laan KO, Breel EJ, Collins PW, Lancé MD, Henskens YMC, Cosemans JMEM, Heemskerk JWM, van der Meijden PEJ. Platelet Control of Fibrin Distribution and Microelasticity in Thrombus Formation Under Flow. Arterioscler Thromb Vasc Biol 2016; 36:692-9. [PMID: 26848157 DOI: 10.1161/atvbaha.115.306537] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2015] [Accepted: 01/15/2016] [Indexed: 01/07/2023]
Abstract
OBJECTIVE Platelet- and fibrin-dependent thrombus formation is regulated by blood flow and exposure of collagen and tissue factor. However, interactions between these blood-borne and vascular components are not well understood. APPROACH AND RESULTS Here, we developed a method to assess whole-blood thrombus formation on microspots with defined amounts of collagen and tissue factor, allowing determination of the mechanical properties and intrathrombus composition. Confining the collagen content resulted in diminished platelet deposition and fibrin formation at high shear flow conditions, but this effect was compensated by a larger thrombus size and increased accumulation of fibrin in the luminal regions of the thrombi at the expense of the base regions. These thrombi were more dependent on tissue factor-triggered thrombin generation. Microforce nanoindentation analysis revealed a significantly increased microelasticity of thrombi with luminal-oriented fibrin. At a low shear rate, fibrin fibers tended to luminally cover the thrombi, again resulting in a higher microelasticity. Studies with blood from patients with distinct hemostatic insufficiencies indicated an impairment in the formation of a platelet-fibrin thrombus in the cases of dilutional coagulopathy, thrombocytopenia, Scott syndrome, and hemophilia B. CONCLUSIONS Taken together, our data indicate that (1) thrombin increases the platelet thrombus volume; (2) tissue factor drives the formation of fibrin outside of the platelet thrombus; (3) limitation of platelet adhesion redirects fibrin from bottom to top of the thrombus; (4) a lower shear rate promotes thrombus coverage with fibrin; (5) the fibrin distribution pattern determines thrombus microelasticity; and (6) the thrombus-forming process is reduced in patients with diverse hemostatic defects.
Collapse
Affiliation(s)
- Frauke Swieringa
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Constance C F M J Baaten
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Remco Verdoold
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Tom G Mastenbroek
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Niek Rijnveld
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Koen O van der Laan
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Ernst J Breel
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Peter W Collins
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Marcus D Lancé
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Yvonne M C Henskens
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Judith M E M Cosemans
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Johan W M Heemskerk
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands
| | - Paola E J van der Meijden
- From the Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands (F.S., C.C.F.M.J.B., R.V., T.G.M., J.M.E.M.C., J.W.M.H., P.E.J.v.d.M.); Research and Development, Optics11, Amsterdam, The Netherlands (N.R., K.O.v.d.L., E.J.B.); Arthur Bloom Haemophilia Centre, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom (P.W.C.); and Central Diagnostic Laboratory (Y.M.C.H.), Departments of Anaesthesiology (M.D.L.) and Internal Medicine (Y.M.C.H.), Maastricht University Medical Center, Maastricht, The Netherlands.
| |
Collapse
|
53
|
Hirigoyen D, Burgos PI, Mezzano V, Duran J, Barrientos M, Saez CG, Panes O, Mezzano D, Iruretagoyena M. Inhibition of angiogenesis by platelets in systemic sclerosis patients. Arthritis Res Ther 2015; 17:332. [PMID: 26584613 PMCID: PMC4653832 DOI: 10.1186/s13075-015-0848-2] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Accepted: 11/04/2015] [Indexed: 01/07/2023] Open
Abstract
INTRODUCTION Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by microvascular damage, inflammation, and fibrosis. It has become increasingly evident that platelets, beyond regulating hemostasis, are important in inflammation and innate immunity. Platelets may be an important source of proinflammatory and profibrotic cytokines in the vascular microenvironment. In this study, we sought to assess the contribution of platelet-derived factors in patients with SSc to the angiogenesis of human dermal microvascular endothelial cells (DMVECs) in a tubule formation assay and to characterize the secretion of profibrotic and proinflammatory cytokines in these platelets. METHODS We analyzed platelets obtained from 30 patients with SSc and 12 healthy control subjects. Angiogenesis was evaluated in vitro with a DMVEC tubule formation assay on Matrigel and platelet-derived angiogenic factors such as vascular endothelial growth factor (VEGF), 165b isoform (VEGF165b), and cytokine secretion was evaluated. Platelet serotonin content was also determined. RESULTS When DMVECs were incubated with SSc platelet releasates, tubule formation was significantly inhibited (p < 0.01, t test), and higher expression of endothelin-1 in these cells was observed compared with control subjects (p < 0.05, Mann-Whitney U test). In SSc platelet releasates, VEGF165b was significantly higher (p < 0.05, t test), and the VEGF165b/VEGF ratio was increased compared with that of control subjects. Higher secretion of transforming growth factor β (p < 0.01, t test) and CD40L (p < 0.01, t test) was observed compared with control subjects. Also, intraplatelet serotonin levels were lower in platelets obtained from patients with diffuse SSc compared with patients with limited SSc and control subjects (p < 0.05, t test). CONCLUSIONS Our findings suggest that antiangiogenic factors such as VEGF165b, together with proinflammatory and profibrotic factors secreted by platelets, can contribute to the progression of peripheral microvascular damage, defective vascular repair, and fibrosis in patients with SSc.
Collapse
Affiliation(s)
- Daniela Hirigoyen
- Departamento de Inmunología Clínica y Reumatología, Pontificia Universidad Católica de Chile, Marcoleta 350, Santiago, Chile.
| | - Paula I Burgos
- Departamento de Inmunología Clínica y Reumatología, Pontificia Universidad Católica de Chile, Marcoleta 350, Santiago, Chile.
| | - Veronica Mezzano
- Departamento de Inmunología Clínica y Reumatología, Pontificia Universidad Católica de Chile, Marcoleta 350, Santiago, Chile.
| | - Josefina Duran
- Departamento de Inmunología Clínica y Reumatología, Pontificia Universidad Católica de Chile, Marcoleta 350, Santiago, Chile.
| | - Magaly Barrientos
- Departamento de Inmunología Clínica y Reumatología, Pontificia Universidad Católica de Chile, Marcoleta 350, Santiago, Chile.
| | - Claudia G Saez
- Departamento de Hematología-Oncología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | - Olga Panes
- Departamento de Hematología-Oncología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | - Diego Mezzano
- Departamento de Hematología-Oncología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | - Mirentxu Iruretagoyena
- Departamento de Inmunología Clínica y Reumatología, Pontificia Universidad Católica de Chile, Marcoleta 350, Santiago, Chile.
| |
Collapse
|
54
|
Ruf W. Diverse packaging of TF into platelets. Thromb Haemost 2015; 114:445. [PMID: 26145707 DOI: 10.1160/th15-06-0451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 06/03/2015] [Indexed: 11/05/2022]
Affiliation(s)
- Wolfram Ruf
- Wolfram Ruf, Center for Thrombosis and Haemostasis, University Medical Center, Mainz, Germany, E-mail:
| |
Collapse
|
55
|
Orellana R, Kato S, Erices R, Bravo ML, Gonzalez P, Oliva B, Cubillos S, Valdivia A, Ibañez C, Brañes J, Barriga MI, Bravo E, Alonso C, Bustamente E, Castellon E, Hidalgo P, Trigo C, Panes O, Pereira J, Mezzano D, Cuello MA, Owen GI. Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells. BMC Cancer 2015; 15:290. [PMID: 25886038 PMCID: PMC4410584 DOI: 10.1186/s12885-015-1304-z] [Citation(s) in RCA: 77] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Accepted: 03/31/2015] [Indexed: 12/17/2022] Open
Abstract
Background An increase in circulating platelets, or thrombocytosis, is recognized as an independent risk factor of bad prognosis and metastasis in patients with ovarian cancer; however the complex role of platelets in tumor progression has not been fully elucidated. Platelet activation has been associated with an epithelial to mesenchymal transition (EMT), while Tissue Factor (TF) protein expression by cancer cells has been shown to correlate with hypercoagulable state and metastasis. The aim of this work was to determine the effect of platelet-cancer cell interaction on TF and “Metastasis Initiating Cell (MIC)” marker levels and migration in ovarian cancer cell lines and cancer cells isolated from the ascetic fluid of ovarian cancer patients. Methods With informed patient consent, ascitic fluid isolated ovarian cancer cells, cell lines and ovarian cancer spheres were co-cultivated with human platelets. TF, EMT and stem cell marker levels were determined by Western blotting, flow cytometry and RT-PCR. Cancer cell migration was determined by Boyden chambers and the scratch assay. Results The co-culture of patient-derived ovarian cancer cells with platelets causes: 1) a phenotypic change in cancer cells, 2) chemoattraction and cancer cell migration, 3) induced MIC markers (EMT/stemness), 3) increased sphere formation and 4) increased TF protein levels and activity. Conclusions We present the first evidence that platelets act as chemoattractants to cancer cells. Furthermore, platelets promote the formation of ovarian cancer spheres that express MIC markers and the metastatic protein TF. Our results suggest that platelet-cancer cell interaction plays a role in the formation of metastatic foci. Electronic supplementary material The online version of this article (doi:10.1186/s12885-015-1304-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Renan Orellana
- Departament of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile. .,Biomedical Research Consortium of Chile, Alameda 440, Piso 13, Santiago, Chile.
| | - Sumie Kato
- Department of Obstetrics and Gynecology, Pontificia Universidad Católica de Chile, Santiago, Chile. .,Biomedical Research Consortium of Chile, Alameda 440, Piso 13, Santiago, Chile.
| | - Rafaela Erices
- Department of Obstetrics and Gynecology, Pontificia Universidad Católica de Chile, Santiago, Chile. .,Biomedical Research Consortium of Chile, Alameda 440, Piso 13, Santiago, Chile.
| | - María Loreto Bravo
- Departament of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile. .,Biomedical Research Consortium of Chile, Alameda 440, Piso 13, Santiago, Chile.
| | - Pamela Gonzalez
- Departament of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile. .,Biomedical Research Consortium of Chile, Alameda 440, Piso 13, Santiago, Chile.
| | - Bárbara Oliva
- Departament of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile. .,Biomedical Research Consortium of Chile, Alameda 440, Piso 13, Santiago, Chile.
| | - Sofía Cubillos
- Departament of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | - Andrés Valdivia
- Departament of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | - Carolina Ibañez
- Division de Hematology & Oncology, Faculty of Medicine, Santiago, Chile. .,Center UC Investigation in Oncology, Santiago, Chile.
| | - Jorge Brañes
- Department of Obstetrics and Gynecology, Pontificia Universidad Católica de Chile, Santiago, Chile.
| | | | - Erasmo Bravo
- Hospital Gustavo Fricke, Viña de Mar, Santiago, Chile.
| | | | - Eva Bustamente
- Fundación Arturo López Pérez, Av. Rancagua 878, Providencia, Santiago, Chile.
| | - Enrique Castellon
- Institute of Biomedical Sciences (ICBM), Faculty of Medicine, Universidad de Chile Avda, Independencia 1027, Santiago, Chile.
| | - Patricia Hidalgo
- Division de Hematology & Oncology, Faculty of Medicine, Santiago, Chile.
| | - Cesar Trigo
- Division de Hematology & Oncology, Faculty of Medicine, Santiago, Chile.
| | - Olga Panes
- Division de Hematology & Oncology, Faculty of Medicine, Santiago, Chile.
| | - Jaime Pereira
- Division de Hematology & Oncology, Faculty of Medicine, Santiago, Chile.
| | - Diego Mezzano
- Division de Hematology & Oncology, Faculty of Medicine, Santiago, Chile. .,Center UC Investigation in Oncology, Santiago, Chile.
| | - Mauricio A Cuello
- Department of Obstetrics and Gynecology, Pontificia Universidad Católica de Chile, Santiago, Chile. .,Center UC Investigation in Oncology, Santiago, Chile. .,Biomedical Research Consortium of Chile, Alameda 440, Piso 13, Santiago, Chile.
| | - Gareth I Owen
- Departament of Physiology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile. .,Center UC Investigation in Oncology, Santiago, Chile. .,Advanced Center for Chronic Diseases (ACCDiS), Pontificia Universidad Católica de Chile, Alameda 340, Santiago, Chile. .,Biomedical Research Consortium of Chile, Alameda 440, Piso 13, Santiago, Chile.
| |
Collapse
|
56
|
Abstract
Epidemiologic studies have revealed that modification of the levels of individual components of the hemostatic system may have effects on the development of thrombosis or hemorrhage. To maintain the necessary equilibrium, the hemostatic system is finely regulated. It is known that acquired factors and/or alterations in genes (single-nucleotide polymorphisms or mutations) may be the cause of interindividual differences or exacerbated levels of hemostatic proteins in plasma, but there are still many non-characterized factors that provoke such variations. The search for new elements, such as microRNAs (miRNAs), a family of small non-coding RNAs that are novel regulators of protein expression, may reveal an additional layer at which to investigate the causes of hemostatic diseases. In this review, we discuss the latest developments in research into the role of miRNAs in the regulation of several hemostatic factors, and the potential use of miRNAs as prognostic or diagnostic tools in hemostasis and thrombosis.
Collapse
Affiliation(s)
- R Teruel-Montoya
- Centro Regional de Hemodonación, IMIB-Arrixaca, University of Murcia, Murcia, Spain
| | | | | |
Collapse
|
57
|
Hess K. The vulnerable blood. Coagulation and clot structure in diabetes mellitus. Hamostaseologie 2014; 35:25-33. [PMID: 25418205 DOI: 10.5482/hamo-14-09-0039] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Accepted: 11/11/2014] [Indexed: 01/04/2023] Open
Abstract
Patients with diabetes are at increased risk of cardiovascular morbidity and mortality. While arteriosclerotic lesions have long been recognized as the underlying cause more recent studies suggest that alterations of the blood are also critically involved. Following plaque rupture, adherence of platelets is followed by the formation of a cross-linked fibrin clot. Patients with diabetes exhibit a prothrombotic milieu consisting of hyper reactive platelets, a tight and rigid clot structure which is due to up-regulation of coagulation factors and prolongation of clot lysis. Metabolic alterations as well as inflammatory processes, which are up-regulated in diabetes, are thought to be the main underlying causes. More recently, the complement cascade has emerged as a potential new player in this context with several complement components directly influencing both platelet function and coagulation. This review provides an overview concerning the changes that lead to alterations of platelet function and clot structure in diabetes.
Collapse
Affiliation(s)
- K Hess
- Dr. Katharina Hess, Department of Internal Medicine I, University Hospital Pauwelsstr. 30, 52074 Aachen, Germany, Tel. +49/(0)241/803 71 28, Fax +49/(0)241/808 25 45, E-mail:
| |
Collapse
|
58
|
Walenga JM, Kaiser PC, Prechel MM, Hoppensteadt D, Jeske WP, Misselwitz F, Bacher P, Lassen MR, Fareed J. Sustained release of tissue factor following thrombosis of lower limb trauma. Clin Appl Thromb Hemost 2014; 20:678-86. [PMID: 25115761 DOI: 10.1177/1076029614545212] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
This study was undertaken to provide evidence for the mechanism of venous thromboembolism (VTE) in healthy patients with minor lower limb injury (fracture; Achilles tendon rupture) that was medically managed with plaster cast/brace immobilization. The Plaster Cast clinical trial provided a unique opportunity to identify the natural history of VTE using placebo-controlled patients (n = 183) with validation of the mechanism using the low-molecular-weight heparin (LMWH; reviparin)-treated patients (n = 182). Confirmed VTE in this population was associated with a burst of tissue factor release (and a minor fibrinolytic deficit) leading to thrombin generation that was sustained at least 5 weeks, greater with fractures than with soft-tissue injuries and greater with surgery than with conservative treatment. The root cause likely involves platelet/leukocyte activation (inflammation) rather than endothelial cell injury. Thromboprophylaxis with a low dose of LMWH reduced thrombin generation, with patients undergoing surgery benefitting the most.
Collapse
Affiliation(s)
- Jeanine M Walenga
- Department of Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL, USA Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
| | - Phoebe C Kaiser
- Department of Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL, USA
| | - M Margaret Prechel
- Department of Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL, USA Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
| | - Debra Hoppensteadt
- Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
| | - Walter P Jeske
- Department of Thoracic & Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL, USA Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
| | - Frank Misselwitz
- Cardiovascular and Coagulation Therapeutics, Bayer Healthcare, Wuppertal, Germany
| | - Peter Bacher
- Global Pharmaceutical R&D, AbbVie, North Chicago, IL, USA
| | - Michael R Lassen
- Spine Center, Glostrup Hospital, University of Copenhagen, Denmark
| | - Jawed Fareed
- Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
| |
Collapse
|
59
|
|
60
|
Iwase H, Ezzelarab MB, Ekser B, Cooper DKC. The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options. Xenotransplantation 2014; 21:201-20. [PMID: 24571124 DOI: 10.1111/xen.12085] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Accepted: 01/08/2014] [Indexed: 12/11/2022]
Abstract
Xenotransplantation could resolve the increasing discrepancy between the availability of deceased human donor organs and the demand for transplantation. Most advances in this field have resulted from the introduction of genetically engineered pigs, e.g., α1,3-galactosyltransferase gene-knockout (GTKO) pigs transgenic for one or more human complement-regulatory proteins (e.g., CD55, CD46, CD59). Failure of these grafts has not been associated with the classical features of acute humoral xenograft rejection, but with the development of thrombotic microangiopathy in the graft and/or consumptive coagulopathy in the recipient. Although the precise mechanisms of coagulation dysregulation remain unclear, molecular incompatibilities between primate coagulation factors and pig natural anticoagulants exacerbate the thrombotic state within the xenograft vasculature. Platelets play a crucial role in thrombosis and contribute to the coagulation disorder in xenotransplantation. They are therefore important targets if this barrier is to be overcome. Further genetic manipulation of the organ-source pigs, such as pigs that express one or more coagulation-regulatory genes (e.g., thrombomodulin, endothelial protein C receptor, tissue factor pathway inhibitor, CD39), is anticipated to inhibit platelet activation and the generation of thrombus. In addition, adjunctive pharmacologic anti-platelet therapy may be required. The genetic manipulations that are currently being tested are reviewed, as are the potential pharmacologic agents that may prove beneficial.
Collapse
Affiliation(s)
- Hayato Iwase
- Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA
| | | | | | | |
Collapse
|
61
|
van der Meijden PEJ, Heemskerk JWM. Polyphosphates: a link between platelet activation, intrinsic coagulation and inflammation? Expert Rev Hematol 2014; 3:269-72. [DOI: 10.1586/ehm.10.26] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
62
|
Platelets do not express the oxidized or reduced forms of tissue factor. Biochim Biophys Acta Gen Subj 2013; 1840:1188-93. [PMID: 24361609 DOI: 10.1016/j.bbagen.2013.11.024] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Revised: 11/11/2013] [Accepted: 11/25/2013] [Indexed: 02/07/2023]
Abstract
BACKGROUND Expression of tissue factor (TF) antigen and activity in platelets is controversial and dependent upon the laboratory and reagents used. Two forms of TF were described: an oxidized functional form and a reduced nonfunctional form that is converted to the active form through the formation of an allosteric disulfide. This study tests the hypothesis that the discrepancies regarding platelet TF expression are due to differential expression of the two forms. METHODS Specific reagents that recognize both oxidized and reduced TF were used in flow cytometry of unactivated and activated platelets and western blotting of whole platelet lysates. TF-dependent activity measurements were used to confirm the results. RESULTS Western blotting analyses of placental TF demonstrated that, in contrast to anti-TF#5, which is directed against the oxidized form of TF, a sheep anti-human TF polyclonal antibody recognizes both the reduced and oxidized forms. Flow cytometric analyses demonstrated that the sheep antibody did not react with the surface of unactivated platelets or platelets activated with thrombin receptor agonist peptide, PAR-1. This observation was confirmed using biotinylated active site-blocked factor (F)VIIa: no binding was observed. Likewise, neither form of TF was detected by western blotting of whole platelet lysates with sheep anti-hTF. Consistent with these observations, no FXa or FIXa generation by FVIIa was detected at the surface of these platelets. Similarly, no TF-related activity was observed in whole blood using thromboelastography. CONCLUSION AND SIGNIFICANCE Platelets from healthy donors do not express either oxidized (functional) or reduced (nonfunctional) forms of TF.
Collapse
|
63
|
Hoppensteadt D, Tsuruta K, Hirman J, Kaul I, Osawa Y, Fareed J. Dysregulation of Inflammatory and Hemostatic Markers in Sepsis and Suspected Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost 2013; 21:120-7. [DOI: 10.1177/1076029613509476] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Inflammatory mediators and hemostatic markers were evaluated in patients enrolled in a phase-2b study evaluating the safety and efficacy of recombinant thrombomodulin (ART-123) in patients with sepsis and suspected disseminated intravascular coagulation (DIC). In contrast to controls, patients with sepsis and suspected DIC showed an increase in the circulating levels of inflammatory and fibrinolytic markers. The levels of procalcitonin (PCT), interleukin 6 (IL-6), interleukin 10 (IL-10), anaphylatoxin C5a, plasminogen activator inhibitor 1 (PAI-1), and myeloperoxidase were higher in the patients with sepsis and suspected DIC, whereas protein C (PrC) exhibited a significant decrease. When the patients with overt and nonovert DIC were compared, the PrC level was lower, and PCT, PAI-1, IL-6, and IL-10 levels were higher in the patients with overt DIC. These results indicate that inflammation is elevated in sepsis and suspected DIC, and inflammation, impairment of fibrinolysis, and overconsumption of PrC may play a key role in the pathogenesis of DIC.
Collapse
Affiliation(s)
| | | | - Joe Hirman
- Pacific Northwest Statistical Consulting, Inc, Woodinville, WA, USA
| | - Inder Kaul
- Asahi Kasei Pharma America Corporation, Waltham, MA, USA
| | - Yutaka Osawa
- Asahi Kasei Pharma America Corporation, Waltham, MA, USA
| | - Jawed Fareed
- Research Laboratories, Loyola University Medical Center, Maywood, IL, USA
| |
Collapse
|
64
|
Jy W, Johansen ME, Bidot C, Horstman LL, Ahn YS. Red cell-derived microparticles (RMP) as haemostatic agent. Thromb Haemost 2013; 110:751-60. [PMID: 24030707 DOI: 10.1160/th12-12-0941] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2013] [Accepted: 07/03/2013] [Indexed: 01/01/2023]
Abstract
Among circulating cell-derived microparticles, those derived from red cells (RMP) have been least well investigated. To exploit potential haemostatic benefit of RMP, we developed a method of producing them in quantity, and here report on their haemostatic properties. High-pressure extrusion of washed RBC was employed to generate RMP. RMP were identified and enumerated by flow cytometry. Their size distribution was assessed by Doppler electrophoretic light scattering analysis (DELSA). Interaction with platelets was studied by platelet aggregometry, and shear-dependent adhesion by Diamed IMPACT-R. Thrombin generation and tissue factor (TF) expression was also measured. The effect of RMP on blood samples of patients with bleeding disorders was investigated ex vivo by thromboelastography (TEG). Haemostatic efficacy in vivo was assessed by measuring reduction of blood loss and bleeding time in rats and rabbits. RMP have mean diameter of 0.45 µm and 50% of them exhibit annexin V binding, a proxy for procoagulant phospholipids (PL). No TF could be detected by flow cytometry. At saturating concentrations of MPs, RMP generated thrombin robustly but after longer delay compared to PMP and EMP. RMP enhanced platelet adhesion and aggregation induced by low-dose ADP or AA. In TEG study, RMP corrected or improved haemostatic defects in blood of patients with platelet and coagulation disorders. RMP reduced bleeding time and blood loss in thrombocytopenic rabbits (busulfan-treated) and in Plavix-treated rats. In conclusion, RMP has broad haemostatic activity, enhancing both primary (platelet) and secondary (coagulation) haemostasis, suggesting potential use as haemostatic agent for treatment of bleeding.
Collapse
Affiliation(s)
- Wenche Jy
- Wenche Jy, PhD, University of Miami Miller School of Medicine, 1600 NW 10th Ave., RMSB 7109, R36-A, Miami, FL 33136, USA, Tel.: +1 305 243 6617, Fax: +1 305 243 5957, E-mail:
| | | | | | | | | |
Collapse
|
65
|
Jarrar YB, Cho SA, Oh KS, Kim DH, Shin JG, Lee SJ. Identification of cytochrome P450s involved in the metabolism of arachidonic acid in human platelets. Prostaglandins Leukot Essent Fatty Acids 2013; 89:227-34. [PMID: 23932368 DOI: 10.1016/j.plefa.2013.06.008] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2013] [Revised: 05/22/2013] [Accepted: 06/30/2013] [Indexed: 01/17/2023]
Abstract
Although cytochrome P450s (CYPs) have been identified in most human cells, identification of CYPs in human platelets remains poorly explored. CYP expressions in human platelets were screened by using reverse transcriptase-polymerase chain reaction and western blot analysis followed by functional assays using arachidonic acid (ARA). CYP1A1, 2U1, 2J2, 4A11, 4F2, and 5A1 were expressed as both proteins and mRNAs in platelets. Ethoxyresorufin-O-deethylase activity was observed in platelets and this activity was significantly decreased after treatment with the general P450 inhibitor SKF-525A and the CYP1A inhibitor, α-naphthoflavone (40-45%, P<0.001). Seventeen ARA metabolites were detected in ARA-treated platelets. Among these, the levels of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids were significantly decreased with the treatment of the P450 ω-hydroxylase inhibitor 17-octadecynoic acid (P<0.05-0.001). In summary, multiple ARA-metabolizing P450s were identified in human platelets. These findings may provide an important resource for understanding physiological function of platelet.
Collapse
Affiliation(s)
- Yazun B Jarrar
- Department of Pharmacology, Pharmacogenomics Research Center, Inje University College of Medicine, Inje University, Busan, South Korea
| | | | | | | | | | | |
Collapse
|
66
|
Matus V, Valenzuela G, Sáez CG, Hidalgo P, Lagos M, Aranda E, Panes O, Pereira J, Pillois X, Nurden AT, Mezzano D. An adenine insertion in exon 6 of human GP6 generates a truncated protein associated with a bleeding disorder in four Chilean families. J Thromb Haemost 2013; 11:1751-9. [PMID: 23815599 DOI: 10.1111/jth.12334] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2013] [Accepted: 06/19/2013] [Indexed: 11/26/2022]
Abstract
BACKGROUND Glycoprotein VI (GPVI), 60-65 kDa, is a major collagen receptor on platelet membranes involved in adhesive and signaling responses. Mice lacking GPVI have impaired platelet response to collagen and defective primary adhesion and subsequent thrombus formation. Complete or partial deficiency of GPVI in humans is a rare condition presenting as a mild bleeding disorder. The defect in most of the reported patients is acquired and associated with other diseases. To date, only two patients have been characterized at the molecular level who carry different compound heterozygous mutations in the GP6 gene. OBJECTIVE To report four unrelated patients from non-consanguineous families who presented with mucocutaneous bleeding. They had absent platelet aggregation and (14) C-5-HT secretion with collagen, convulxin and collagen-related peptide. RESULTS Flow cytometry and immunofluorescence-confocal microscopy showed an absence of GPVI in non-permeabilized platelets. All the patients had an adenine insertion in exon 6 (c.711_712insA), changing the reading frame and generating a premature 'stop codon' in site 242 of the protein. The mutation predicts the synthesis of the truncated protein before the trans-membrane domain, corresponding to a band of ≈49 kDa observed in western blots and in permeabilized platelets by immunofluorescence. Platelet mRNA from all the patients was sequenced and contained the corresponding adenine insertion. Heterozygous relatives had no pathological bleeding, normal response to collagen and convulxin and intermediate membrane expression of GPVI. CONCLUSIONS The identification of four unrelated homozygous patients with an identical defect suggests that inherited GPVI deficiency is more frequent than previously suspected, at least in Chile.
Collapse
Affiliation(s)
- V Matus
- Departments of Hematology-Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
67
|
Garraud O, Hamzeh-Cognasse H, Pozzetto B, Cavaillon JM, Cognasse F. Bench-to-bedside review: Platelets and active immune functions - new clues for immunopathology? CRITICAL CARE : THE OFFICIAL JOURNAL OF THE CRITICAL CARE FORUM 2013; 17:236. [PMID: 23998653 PMCID: PMC4055978 DOI: 10.1186/cc12716] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Platelets display a number of properties besides the crucial function of repairing damaged vascular endothelium and stopping bleeding; these are exploited to benefit patients receiving platelet component transfusions, which might categorize them as innate immune cells. For example, platelets specialize in pro-inflammatory activities, and can secrete a large number of molecules, many of which display biological response modifier functions. Platelets also express receptors for non-self-infectious and possibly non-infectious danger signals, and can engage infectious pathogens by mechanisms barely explained beyond observation. This relationship with infectious pathogens may involve other innate immune cells, especially neutrophils. The sophisticated interplay of platelets with bacteria may culminate in sepsis, a severe pathology characterized by significant reductions in platelet count and platelet dysfunction. How this occurs is still not fully understood. Recent findings from in-depth platelet signaling studies reveal the complexity of platelets and some of the ways they evolve along the immune continuum, from beneficial functions exemplified in endothelium repair to deleterious immunopathology as in systemic inflammatory response syndrome and acute vascular diseases. This review discusses the extended role of platelets as immune cells to emphasize their interactions with infectious pathogens sensed as potentially dangerous.
Collapse
|
68
|
Mackman N, Luther T. Platelet tissue factor: to be or not to be. Thromb Res 2013; 132:3-5. [PMID: 23731564 DOI: 10.1016/j.thromres.2013.05.009] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2013] [Revised: 05/05/2013] [Accepted: 05/07/2013] [Indexed: 10/26/2022]
|
69
|
Human platelets do not express tissue factor. Thromb Res 2013; 132:112-5. [PMID: 23623171 DOI: 10.1016/j.thromres.2013.04.010] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2013] [Revised: 04/09/2013] [Accepted: 04/09/2013] [Indexed: 11/22/2022]
Abstract
BACKGROUND The controversy about the expression of tissue factor (TF) in platelet after de novo synthesis prevail despite many groups recognize that platelet isolation, assays and reagents, particularly non-specific antibodies, may account for the diversity. In this study the potential of TF expression was evaluated using immune-purified human platelets and employing a very sensitive and highly specific TF activity assay. METHODS Isolated platelets in plasma anti-coagulated with Fragmin were subjected to stimulation by LPS plus PMA, IgG antibody or TRAP and tested for TF activity. RESULTS Platelets stimulated with LPS plus PMA for 4 hours expressed trace amounts of TF like activity (PCA), not inhibited by anti-TF antibody (0.2±0.1 mU/ml blood). Platelets, not immune-adsorbed to remove monocytes, showed significant TF activity (2.0±0.9 mU/ml blood) that was nearly abolished by anti-TF antibody. IgG antibody from patient with lupus anticoagulant failed to enhance the trace amount of PCA as compared to the control in contrast to high TF activity induced in monocytes (0.4±0.1 mU/ml blood versus 27.5±10.5 mU/10(6) cells) showing that activation of complement is not mediating TF expression. Platelet subjected to TRAP activation for 10 min possessed only trace amounts of PCA that was not inhibited by anti-TF antibody and slightly enhanced by anti-TFPI antibody. CONCLUSIONS It is concluded that platelets free of monocytes do not express TF activity when stimulated by LPS or activated complement factors, implying no role for Toll like receptor (TLR4) as suggested recently. There is no evidence of TF activity associated with platelets as a result of rapid and dynamic process.
Collapse
|
70
|
Vignoli A, Giaccherini C, Marchetti M, Verzeroli C, Gargantini C, Da Prada L, Giussani B, Falanga A. Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates. ACTA ACUST UNITED AC 2013; 40:126-32. [PMID: 23652779 DOI: 10.1159/000350330] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2013] [Accepted: 02/27/2013] [Indexed: 11/19/2022]
Abstract
BACKGROUND Tissue factor (TF), the main activator of blood coagulation, is expressed on platelet surface and, together with procoagulant phospholipids, contributes to the global coagulation potential of these blood components. The present study evaluated, for the first time, the expression of TF on platelet surface during preparation and storage of platelet concentrates (PC) for transfusional use. METHODS Platelet TF was measured by flow cytometry in healthy donor whole blood (WB) and in pooled buffy-coat-derived PC on the day of preparation and up to 4 days of storage in parallel with classical markers of platelet activation, i.e., fibrinogen, P-selectin, and glycoprotein GPIIb. Data were analyzed according to donor age and blood ABO group. RESULTS TF was detected on whole blood platelets and was found highest in O donors. Compared to whole blood, platelet surface TF was higher upon PC preparation and further increased during storage. The rise in TF levels positively correlated with the elevations of the other platelet markers. CONCLUSIONS Our findings show that platelet surface TF is maintained in PC obtained by the pooled buffy coat method. Further studies are warranted to investigate a possible correlation between TF levels and the hemostatic response of the platelet transfusion recipient.
Collapse
Affiliation(s)
- Alfonso Vignoli
- Division of Immunohematology and Transfusion Medicine, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
| | | | | | | | | | | | | | | |
Collapse
|
71
|
Heemskerk JWM, Mattheij NJA, Cosemans JMEM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013; 11:2-16. [PMID: 23106920 DOI: 10.1111/jth.12045] [Citation(s) in RCA: 237] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Platelets in a thrombus interact with (anti)coagulation factors and support blood coagulation. In the concept of cell-based control of coagulation, three different roles of platelets can be distinguished: control of thrombin generation, support of fibrin formation, and regulation of fibrin clot retraction. Here, we postulate that different populations of platelets with distinct surface properties are involved in these coagulant functions. Platelets with elevated Ca(2+) and exposed phosphatidylserine control thrombin and fibrin generation, while platelets with activated α(IIb) β(3) regulate clot retraction. We review how coagulation factor binding depends on the platelet activation state. Furthermore, we discuss the ligands, platelet receptors and downstream intracellular signaling pathways implicated in these coagulant functions. These insights lead to an adapted model of platelet-based coagulation.
Collapse
Affiliation(s)
- J W M Heemskerk
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.
| | | | | |
Collapse
|
72
|
|
73
|
Butenas S. Tissue factor structure and function. SCIENTIFICA 2012; 2012:964862. [PMID: 24278763 PMCID: PMC3820524 DOI: 10.6064/2012/964862] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/30/2012] [Accepted: 11/19/2012] [Indexed: 06/02/2023]
Abstract
Tissue factor (TF) is an integral membrane protein that is essential to life. It is a component of the factor VIIa-TF complex enzyme and plays a primary role in both normal hemostasis and thrombosis. With a vascular injury, TF becomes exposed to blood and binds plasma factor VIIa, and the resulting complex initiates a series of enzymatic reactions leading to clot formation and vascular sealing. Many cells, both healthy, and tumor cells, produce detectable amounts of TF, especially when they are stimulated by various agents. Despite the relative simplicity and small size of TF, there are numerous contradictory reports about the synthesis and presentation of TF on blood cells and circulation in normal blood either on microparticles or as a soluble protein. Another subject of controversy is related to the structure/function of TF. It has been almost commonly accepted that cell-surface-associated TF has low (if any) activity, that is, is "encrypted" and requires specific conditions/reagents to become active, that is, "decrypted." However there is a lack of agreement related to the mechanism and processes leading to alterations in TF function. In this paper TF structure, presentation, and function, and controversies concerning these features are discussed.
Collapse
Affiliation(s)
- Saulius Butenas
- Department of Biochemistry, University of Vermont, 208 South Park Drive, Room 235A, Colchester, VT 05446, USA
| |
Collapse
|
74
|
|
75
|
Lopez-Vilchez I, Galan AM, Hernandez MR, Caballo C, Roque M, Diaz-Ricart M, White JG, Escolar G. Platelet-associated tissue factor enhances platelet reactivity and thrombin generation in experimental studies in vitro. Thromb Res 2012; 130:e294-300. [DOI: 10.1016/j.thromres.2012.10.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2012] [Revised: 10/05/2012] [Accepted: 10/17/2012] [Indexed: 12/13/2022]
|
76
|
Abstract
PURPOSE OF REVIEW It is now well appreciated that megakaryocytes invest platelets with a diverse repertoire of messenger RNAs (mRNAs), which are competent for translation. Herein we describe what is currently known regarding the expression, function, and clinical significance of mRNAs in platelets. RECENT FINDINGS Although mRNA was detected in platelets nearly 30 years ago, we are only beginning to understand the roles of mRNA in platelet biology and human disease. Recent studies have shown that megakaryocytes specifically sort, rather than randomly transfer, mRNA to platelets during thrombopoiesis. As a result, platelets are released into the circulation with thousands of mRNAs. The emergence of next-generation RNA sequencing has demonstrated that platelet mRNAs possess classic structural features, which include untranslated regions and open reading frames. There is also growing evidence that platelet mRNA expression patterns are altered in human disease. SUMMARY Intense investigation of platelet mRNA has shed considerable light on predicted functions of platelets and identified previously unrecognized attributes of platelets. Lessons learned from platelet mRNA is presented in this review.
Collapse
Affiliation(s)
- Jesse W Rowley
- Molecular Medicine Program, University of Utah, Salt Lake City, USA
| | | | | |
Collapse
|
77
|
Wang GF, Zou XL. Tissue factor with age-related macular degeneration. Int J Ophthalmol 2012; 5:609-13. [PMID: 23166874 DOI: 10.3980/j.issn.2222-3959.2012.05.13] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2012] [Accepted: 09/24/2012] [Indexed: 11/02/2022] Open
Abstract
Wet age-related macular degeneration which incidence increases year by year is a blinding eye disease, but current clinical methods of treatment on this disease are limited and the outcome is not ideal. Recent studies have found abnormally high expression of tissue factors which are targets for the treatment of wet age-related macular degeneration to achieve a certain effect in the choroidal neovascularization. Related literatures are reviewed as following.
Collapse
Affiliation(s)
- Guan-Feng Wang
- Department of Ophthalmology, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou 510010, Guangdong Province, China ; Jinan University, Guangzhou 510630, Guangdong Province, China
| | | |
Collapse
|
78
|
Evidence for direct transfer of tissue factor from monocytes to platelets in whole blood. Blood Coagul Fibrinolysis 2012; 23:345-50. [PMID: 22343684 DOI: 10.1097/mbc.0b013e328350bf2f] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Varying specificity of anti-tissue factor (anti-TF) antibodies gives rise to erroneous conclusions on TF positivity of platelets. Although monocytes are a well established source of TF in whole blood, there is no consensus whether platelets express or acquire TF from external sources. To test whether platelets can acquire TF expressed in monocytes, we studied a transfer of TF-yellow fluorescent protein (TF-YFP) from monocytes nucleofected with TF-YFP to platelets in a whole blood model. Platelets isolated from whole blood were found positive for TF when immunostained with anti-TF antibody from one supplier, whereas no platelet TF antigen was found in whole blood immunostained with anti-TF antibody from another supplier. Both antibodies recognized TF in monocytes. Platelets isolated from whole blood reconstituted with monocytes expressing TF-YFP fusion protein were found positive for TF-YFP only after stimulation with lipopolysaccharide (LPS). Taken together, TF protein could be transferred from monocytes upon stimulation with LPS.
Collapse
|
79
|
Basavaraj MG, Olsen JO, Østerud B, Hansen JB. Differential ability of tissue factor antibody clones on detection of tissue factor in blood cells and microparticles. Thromb Res 2012; 130:538-46. [PMID: 22728024 DOI: 10.1016/j.thromres.2012.06.001] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2011] [Revised: 05/30/2012] [Accepted: 06/04/2012] [Indexed: 10/28/2022]
Abstract
INTRODUCTION Tissue factor (TF), the primary initiator of coagulation in vivo, plays a major role in both thrombosis and hemostasis. The expression of TF in monocytes is well documented, but its presence in other blood cells has been disputed, possibly due to methodological variations among different studies. MATERIALS AND METHODS We studied TF expression on platelets, monocytes, lymphocytes and microparticles (MPs) by flow cytometry (FCM) with five commercially available mouse anti-human TF antibodies (HTF-1, TF9-10H10, CLB/TF-5, VIC7 and VD8). The ability of different TF antibodies to inhibit cell surface TF activity was explored by incubating LPS-stimulated monocytes and MPs derived from LPS-stimulated monocytes (MMPs) with TF antibodies followed by measuring TF activity. RESULTS HTF-1 detected TF only on LPS-stimulated monocytes, whereas, TF9-10H10 and VD8 detected TF associated with MPs and MMPs in addition to LPS stimulated monocytes. Surprisingly, CLB/TF-5 and VIC7 detected TF on platelets, monocytes even under unstimulated conditions, in addition to MPs and MMPs. CLB/TF-5 also detected TF on unstimulated lymphocytes. Inhibitory studies showed that at a final concentration of 10 μg/mL, HTF-1, CLB/TF-5 and VD8 inhibited monocyte TF activity by 81-84% and MMP TF activity by 92-96%; whereas TF9-10H10 had no inhibitory effect on TF activity in monocytes and MMPs. CONCLUSIONS Our results suggest non-specific binding by the CLB/TF-5 and VIC7 antibodies in a FCM test system and explain at least some of the reports on TF presence in blood cells, particularly TF associated with platelets and MPs. TF9-10H10 and VD8 are more suitable to detect TF on MPs by FCM.
Collapse
|
80
|
Abstract
Observational and experimental studies continue to support the association of infection and infection-stimulated inflammation with development of cardiovascular disease (CVD) including atherosclerosis and thrombosis. Microvesicles (MV) are heterogeneous populations of sealed membrane-derived vesicles shed into circulation by activated mammalian cells and/or pathogenic microbes that may represent an interface between bacterial/microbial infection and increased risk of CVD. This review evaluates how MV act to modulate and intersect immunological and inflammatory responses to infection with particular attention to progression of CVD. Although infection-related stimuli provoke release of MV from blood and vascular cells, MV express phosphatidylserine and other procoagulant factors on their surface, which initiate and amplify blood coagulation. In addition, MV mediate cell-cell adhesion, which may stimulate production of pro-inflammatory cytokines in vascular cells, which in turn aggravate progression of CVD and propagate atherothrombosis. MV transfer membrane receptors, RNA and proteins among cells, and present auto-antigens from their cells of origin to proximal or remote target cells. Because MV harbor cell surface proteins and contain cytoplasmic components of the parent cell, they mediate biological messages and play a pivotal role in the crossroad between infection-stimulated inflammation and CVDs.
Collapse
|
81
|
|
82
|
Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr 2012; 59:340-6. [PMID: 22156911 DOI: 10.1097/qai.0b013e3182439355] [Citation(s) in RCA: 122] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE HIV-1-infected patients have an increased risk for atherothrombosis and cardiovascular disease, but the mechanism behind these risks is poorly understood. We have previously reported that expression of tissue factor (TF) on circulating monocytes is increased in persons with HIV infection and that TF expression is related to immune activation, to levels of HIV in plasma, and to indices of microbial translocation. In this study, we explore the activation state of platelets in HIV disease. METHODS Here, using flow cytometry-based assays, we measured platelet and platelet microparticle (PMP) activation in samples from HIV-1-infected donors and controls. RESULTS Platelets and PMPs from HIV-1-infected patients are activated (as reflected by expression of CD62 P-selectin) and also more frequently expressed the procoagulant TF than did platelets and PMPs obtained from controls. Expression of these proteins was directly related to expression of TF on monocytes, to markers of T-cell activation (CD38 and HLA-DR), and to plasma levels of soluble CD14, the coreceptor for bacterial lipopolysaccharride. Platelet and microparticle expression of TF was not related to plasma levels of HIV but expression of P-selectin was related to plasma levels of HIV; neither TF nor P-selectin expression was related to CD4 T-cell count. CONCLUSIONS Platelets and microparticles are activated in HIV infection, and this activated phenotype may contribute to the increased risk for cardiovascular and thrombotic events in this population although a role for other confounding cardiovascular risks cannot be completely excluded.
Collapse
|
83
|
PALOMO IVÁN, FUENTES EDUARDO, PADRÓ TERESA, BADIMON LINA. Platelets and atherogenesis: Platelet anti-aggregation activity and endothelial protection from tomatoes (Solanum lycopersicum L.). Exp Ther Med 2012; 3:577-584. [PMID: 22969932 PMCID: PMC3438755 DOI: 10.3892/etm.2012.477] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2011] [Accepted: 12/19/2011] [Indexed: 02/03/2023] Open
Abstract
In recent years, it has been shown that platelets are not only involved in the arterial thrombotic process, but also that they play an active role in the inflammatory process of atherogenesis from the beginning. The interaction between platelets and endothelial cells occurs in two manners: activated platelets unite with intact endothelial cells, or platelets in resting adhere to activated endothelium. In this context, inhibition of the platelet function (adhesion/aggregation) could contribute to the prevention of atherothrombosis, the leading cause of cardiovascular morbidity. This can be achieved with antiplatelet agents. However, at the public health level, the level of primary prevention, a healthy diet has also been shown to exert beneficial effects. Among those elements of a healthy diet, the consumption of tomatoes (Solanum lycopersicum L.) stands out for its effect on platelet anti-aggregation activity and endothelial protection, which may be beneficial for cardiovascular health. This article briefly discusses the involvement of platelets in atherogenesis and the possible mechanisms of action provided by tomatoes for platelet anti-aggregation activity and endothelial protection.
Collapse
Affiliation(s)
- IVÁN PALOMO
- Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, University of Talca
- Centro de Estudios en Alimentos Procesados (CEAP), Conicyt-Regional, Gore Maule, Talca,
Chile
| | - EDUARDO FUENTES
- Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, University of Talca
- Centro de Estudios en Alimentos Procesados (CEAP), Conicyt-Regional, Gore Maule, Talca,
Chile
| | - TERESA PADRÓ
- Cardiovascular Research Center (CSIC-ICCC), Hospital de la Santa Creu i Sant Pau-Instituto de Investigación Biomédica Sant Pau, CiberOBENU, Instituto Carlos III, Barcelona,
Spain
| | - LINA BADIMON
- Cardiovascular Research Center (CSIC-ICCC), Hospital de la Santa Creu i Sant Pau-Instituto de Investigación Biomédica Sant Pau, CiberOBENU, Instituto Carlos III, Barcelona,
Spain
| |
Collapse
|
84
|
Abstract
Tissue factor plays a primary role in both hemorrhage control and thrombosis depending upon whether its presentation is extravascular or intravascular. The molecular architecture and function of the tissue factor molecule and its role in the activations of factor IX and factor X have been elegantly elucidated but controversies prevail with respect to distinctions between tissue factor sources and tissue factor "activity." This presentation will review data on the architecture and functions of the tissue factor-factor VIIa complex and discuss the elements of the controversies associated with tissue factor presentation in both normal and pathologic milieu.
Collapse
Affiliation(s)
- Kenneth G Mann
- University of Vermont, Department of Biochemistry, Burlington, VT, [corrected] USA.
| | | | | |
Collapse
|
85
|
Sepsis, thrombosis and organ dysfunction. Thromb Res 2012; 129:290-5. [DOI: 10.1016/j.thromres.2011.10.013] [Citation(s) in RCA: 221] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2011] [Revised: 09/16/2011] [Accepted: 10/14/2011] [Indexed: 02/07/2023]
|
86
|
Wiinberg B, Jessen LR, Tarnow I, Kristensen AT. Diagnosis and treatment of platelet hyperactivity in relation to thrombosis in dogs and cats. J Vet Emerg Crit Care (San Antonio) 2012; 22:42-58. [DOI: 10.1111/j.1476-4431.2011.00708.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Bo Wiinberg
- From the Department of Small Animal Clinical Sciences; Faculty of Life Sciences; University of Copenhagen; DK-1810 Frederiksberg; Denmark
| | - Lisbeth R. Jessen
- From the Department of Small Animal Clinical Sciences; Faculty of Life Sciences; University of Copenhagen; DK-1810 Frederiksberg; Denmark
| | - Inge Tarnow
- Health & Nutrition Division; Chr. Hansen A/S; DK-2970 Hørsholm; Denmark
| | - Annemarie T. Kristensen
- From the Department of Small Animal Clinical Sciences; Faculty of Life Sciences; University of Copenhagen; DK-1810 Frederiksberg; Denmark
| |
Collapse
|
87
|
Abstract
Initiation of blood coagulation occurs mainly through tissue factor (TF) that becomes exposed to blood following vascular injury. Cell-associated TF binds to the serine protease FVIIa and initiates a cascade of amplified zymogen activation reactions leading to thrombus formation. As TF-FVIIa directed inhibitors might achieve anticoagulant efficacy without significantly interfering with normal haemostasis, the TF-FVIIa complex is an interesting target in thrombosis-related disease. Various approaches have been used to inhibit the TF-FVIIa complex including active site-inhibited FVIIa, TF antibodies, tissue factor pathway inhibitor (TFPI), naturally occurring inhibitors, peptide exosite inhibitors and active site inhibitors. Several experimental studies using these inhibitors have displayed promise. However, none of these TF/FVIIa inhibitors has reached clinical testing. Further studies are required to evaluate the clinical efficacy of these novel inhibitors.
Collapse
Affiliation(s)
- Ilka Ott
- Deutsches Herzzentrum der Technischen Universität München, München, Germany.
| |
Collapse
|
88
|
Fasano A, Santos RF, Sequeira A. Blood coagulation: A puzzle for biologists, a maze for mathematicians. MS&A 2012. [DOI: 10.1007/978-88-470-1935-5_3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
89
|
Osterud B. Tissue factor/TFPI and blood cells. Thromb Res 2011; 129:274-8. [PMID: 22197177 DOI: 10.1016/j.thromres.2011.11.049] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2011] [Revised: 11/21/2011] [Accepted: 11/22/2011] [Indexed: 10/14/2022]
Abstract
Vascular injury-induced access of blood to tissue factor (TF) leads to the formation of a TF-FVII/FVIIa complex and the triggering of blood coagulation. The activated TF-dependent pathway is regulated by Tissue Factor Pathway Inhibitor (TFPI), which binds and inhibits FXa, but more importantly forms an inactive quaternary complex with TF-FVIIa-FXa, effectively shutting off the TF activity. The old view of TF residing in extravascular sites exclusively has recently been challenged by several reports on TF expression in various blood cells. The latter arena has unfortunately been marred by many contradictions, apparently related to inferior tools and/or study design, notably the widespread use of antibodies with inferior and misleading specificity and TF activity assays of low sensitivity/specificity. Our own studies along with many other reports, compels the conclusion that in blood of healthy individuals TF is exclusively associated with and expressed in circulating monocytes. In this short review the distribution of TF and TFPI in blood is discussed.
Collapse
Affiliation(s)
- Bjarne Osterud
- HERG, Department of Medical Biology, Faculty of Health Sciences and MabCent SFI, University of Tromsø, 9037 Tromsø, Norway.
| |
Collapse
|
90
|
Tissue factor and atherosclerosis: not only vessel wall-derived TF, but also platelet-associated TF. Thromb Res 2011; 129:279-84. [PMID: 22178579 DOI: 10.1016/j.thromres.2011.11.028] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2011] [Revised: 11/14/2011] [Accepted: 11/16/2011] [Indexed: 11/20/2022]
Abstract
In the last ten years the contribution of both vessel wall-derived tissue factor (TF) and platelets to atherosclerosis has been revisited. At the beginning of the 2000 a circulating blood-borne TF has been proposed to sustain coagulation activation and propagation on the edge of a growing thrombus. Concomitantly with the observation that platelets not only contribute to thrombus formation, but also take part to the onset of the atherosclerotic lesion, evidences have been provided that they express functionally active TF, making them able to trigger the coagulation cascade.
Collapse
|
91
|
Abstract
For many years, programmed cell death, known as apoptosis, was attributed exclusively to nucleated cells. Currently, however, apoptosis is also well-documented in anucleate platelets. This review describes extrinsic and intrinsic pathways of apoptosis in nucleated cells and in platelets, platelet apoptosis induced by multiple chemical stimuli and shear stresses, markers of platelet apoptosis, mitochodrial control of platelet apoptosis, and apoptosis mediated by platelet surface receptors PAR-1, GPIIbIIIa and GPIbα. In addition, this review presents data on platelet apoptosis provoked by aging of platelets in vitro during platelet storage, platelet apoptosis in pathological settings in humans and animal models, and inhibition of platelet apoptosis by cyclosporin A, intravenous immunoglobulin and GPIIbIIIa antagonist drugs.
Collapse
Affiliation(s)
- Valery Leytin
- Division of Transfusion Medicine, Department of Laboratory Medicine, The Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada.
| |
Collapse
|
92
|
Tormoen GW, Rugonyi S, Gruber A, McCarty OJT. The role of carrier number on the procoagulant activity of tissue factor in blood and plasma. Phys Biol 2011; 8:066005. [PMID: 22048420 DOI: 10.1088/1478-3975/8/6/066005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Tissue factor (TF) is a transmembrane glycoprotein cofactor of activated blood coagulation factor VII (FVIIa) that is required for hemostatic thrombin generation at sites of blood vessel injury. Membrane-associated TF detected in circulating blood of healthy subjects, referred to as intravascular or circulating TF has been shown to contribute to experimental thrombus propagation at sites of localized vessel injury. Certain disease states, such as metastatic cancer, are associated with increased levels of intravascular TF and an elevated risk of venous thromboembolism. However, the physiological relevance of circulating TF to hemostasis or thrombosis, as well as cancer metastasis, is ill-defined. This study was designed to assess whether the spatial separation of intravascular TF carriers in blood, demonstrated with TF-inducible human monocytic cell line U937 or TF-coated polymer microspheres, affected procoagulant activity and hence thrombogenic potential. Experiments were performed to characterize the effects of TF-carrier number on the kinetics of clot formation in both open and closed systems. The procoagulant activity of TF carriers was found to correlate with spatial separation in both closed, well-mixed systems and open, flowing systems. TF carriers enhanced the amidolytic activity of FVIIa toward the chromogenic substrate, S-2366, as a function of carrier count. These results suggest that TF-initiated coagulation by circulating TF is kinetically limited by mass transport of TF-dependent coagulation factors to the TF-bearing surface, a constraint that may be unique to circulating TF. Spatial separation of circulating TF carriers is therefore a critical determinant of the procoagulant activity of circulating TF.
Collapse
Affiliation(s)
- G W Tormoen
- Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA
| | | | | | | |
Collapse
|
93
|
Colace TV, Jobson J, Diamond SL. Relipidated tissue factor linked to collagen surfaces potentiates platelet adhesion and fibrin formation in a microfluidic model of vessel injury. Bioconjug Chem 2011; 22:2104-9. [PMID: 21902184 DOI: 10.1021/bc200326v] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Microfluidic devices allow for the controlled perfusion of human or mouse blood over defined prothrombotic surfaces at venous and arterial shear rates. To mimic in vivo injuries such a plaque rupture, the need exists to link lipidated tissue factor (TF) to surface-bound collagen fibers. Recombinant TF was relipidated in liposomes of phosphatidylserine/phosphatidylcholine/biotin-linked phosphatidylethanolamine (20:79:1 PS/PC/bPE molar ratio). Collagen was patterned in a 250-μm-wide stripe and labeled with biotinylated anticollagen antibody which was then bound with streptavidin, allowing the subsequent capture of the TF liposomes. To verify and detect the TF liposome-collagen assembly, individual molecular complexes of TF-factor VIIa on collagen were visualized using the proximity ligation assay (PLA) to produce discretely localized fluorescent events that were strictly dependent on the presence of factor VIIa and primary antibodies against TF or factor VIIa. Perfusion for 450 s (wall shear rate, 200 s(-1)) of corn trypsin inhibitor (CTI, a factor XIIa inhibitor) treated whole blood over the stripe of TF-collagen enhanced platelet adhesion by 30 ± 8% (p < 0.001) and produced measurable fibrin (>50-fold increase) as compared to surfaces lacking TF. PS/PC/bPE liposomes lacking TF resulted in no enhancement of platelet deposition. Essentially no fibrin was formed during perfusion over collagen surfaces or collagen surfaces with liposomes lacking TF despite the robust platelet deposition, indicating a lack of kinetically significant platelet-borne tissue factor in healthy donor blood. This study demonstrates a reliable approach to link functionally active TF to collagen for microfluidic thrombosis studies.
Collapse
Affiliation(s)
- Thomas V Colace
- Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, Pennsylvania, United States
| | | | | |
Collapse
|
94
|
Vieira-de-Abreu A, Campbell RA, Weyrich AS, Zimmerman GA. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol 2011; 34:5-30. [PMID: 21818701 DOI: 10.1007/s00281-011-0286-4] [Citation(s) in RCA: 217] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2011] [Accepted: 07/20/2011] [Indexed: 12/28/2022]
Abstract
Platelets are chief effector cells in hemostasis. In addition, however, their specializations include activities and intercellular interactions that make them key effectors in inflammation and in the continuum of innate and adaptive immunity. This review focuses on the immune features of human platelets and platelets from experimental animals and on interactions between inflammatory, immune, and hemostatic activities of these anucleate but complex and versatile cells. The experimental findings and evidence for physiologic immune functions include previously unrecognized biologic characteristics of platelets and are paralleled by new evidence for unique roles of platelets in inflammatory, immune, and thrombotic diseases.
Collapse
Affiliation(s)
- Adriana Vieira-de-Abreu
- Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT 84112, USA
| | | | | | | |
Collapse
|
95
|
Panes O, Padilla O, Matus V, Sáez CG, Berkovits A, Pereira J, Mezzano D. Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid. Platelets 2011; 23:36-44. [PMID: 21787173 DOI: 10.3109/09537104.2011.596957] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Fibrinolysis dysfunctions cause bleeding or predisposition to thrombosis. Platelets contain several factors of the fibrinolytic system, which could up or down regulate this process. However, the temporal relationship and relative contributions of plasma and platelet components in clot lysis are mostly unknown. We developed a clot lysis time (CLT) assay in platelet-rich plasma (PRP-CLT, with and without stimulation) and compared it to a similar one in platelet-free plasma (PFP) and to another previously reported test in platelet-poor plasma (PPP). We also studied the differential effects of a single dose of tranexamic acid (TXA) on these tests in healthy subjects. PFP- and PPP-CLT were significantly shorter than PRP-CLT, and the three assays were highly correlated (p < 0.0001). PFP- and PPP-, but more significantly PRP-CLT, were positively correlated with age and plasma PAI-1, von Willebrand factor, fibrinogen, LDL-cholesterol, and triglycerides (p < 0.001). All these CLT assays had no significant correlations with platelet aggregation/secretion, platelet counts, and pro-coagulant tests to explore factor X activation by platelets, PRP clotting time, and thrombin generation in PRP. Among all the studied variables, PFP-CLT was independently associated with plasma PAI-1, LDL-cholesterol, and triglycerides and, additionally, stimulated PRP-CLT was also independently associated with plasma fibrinogen. A single 1 g dose of TXA strikingly prolonged all three CLTs, but in contrast to the results without the drug, the lysis times were substantially shorter in non-stimulated or stimulated PRP than in PFP and PPP. This standardized PRP-CLT may become a useful tool to study the role of platelets in clot resistance and lysis. Our results suggest that initially, the platelets enmeshed in the clot slow down the fibrinolysis process. However, the increased clot resistance to lysis induced by TXA is overcome earlier in platelet-rich clots than in PFP or PPP clots. This is likely explained by the display of platelet pro-fibrinolytic effects. Focused research is needed to disclose the mechanisms for the relationship between CLT and plasma cholesterol and its potential pathophysiologic and clinical relevance.
Collapse
Affiliation(s)
- Olga Panes
- Department of Hematology-Oncology, School of Medicine, P. Catholic University of Chile, Santiago, Chile
| | | | | | | | | | | | | |
Collapse
|
96
|
Abstract
Blood contains microparticles (MPs) derived from a variety of cell types, including platelets, monocytes, and endothelial cells. In addition, tumors release MPs into the circulation. MPs are formed from membrane blebs that are released from the cell surface by proteolytic cleavage of the cytoskeleton. All MPs are procoagulant because they provide a membrane surface for the assembly of components of the coagulation protease cascade. Importantly, procoagulant activity is increased by the presence of anionic phospholipids, particularly phosphatidylserine (PS), and the procoagulant protein tissue factor (TF), which is the major cellular activator of the clotting cascade. High levels of platelet-derived PS(+) MPs are present in healthy individuals, whereas the number of TF(+), PS(+) MPs is undetectable or very low. However, levels of PS(+), TF(+) MPs are readily detected in a variety of diseases, and monocytes appear to be the primary cellular source. In cancer, PS(+), TF(+) MPs are derived from tumors and may serve as a useful biomarker to identify patients at risk for venous thrombosis. This review will summarize our current knowledge of the role of procoagulant MPs in hemostasis and thrombosis.
Collapse
Affiliation(s)
- A Phillip Owens
- Division of Hematology/Oncology, Department of Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill, North Carolina, USA
| | | |
Collapse
|
97
|
The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. PPAR Res 2011; 2008:328172. [PMID: 18288284 PMCID: PMC2233896 DOI: 10.1155/2008/328172] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2007] [Accepted: 11/06/2007] [Indexed: 01/08/2023] Open
Abstract
Historically, platelets were viewed as simple anucleate cells responsible for initiating thrombosis and maintaining
hemostasis, but clearly they are also key mediators of inflammation and immune cell activation. An emerging body of
evidence links platelet function and thrombosis to vascular inflammation. peroxisome proliferator-activated receptors
(PPARs) play a major role in modulating inflammation and, interestingly, PPARs (PPARβ/δ and PPARγ) were recently
identified in platelets. Additionally, PPAR agonists attenuate platelet activation; an important discovery for two reasons.
First, activated platelets are formidable antagonists that initiate and prolong a cascade of events that contribute to
cardiovascular disease (CVD) progression. Dampening platelet release of proinflammatory mediators, including
CD40 ligand (CD40L, CD154), is essential to hinder this cascade. Second, understanding the biologic importance
of platelet PPARs and the mechanism(s) by which PPARs regulate platelet activation will be imperative in designing
therapeutic strategies lacking the deleterious or unwanted side effects of current treatment options.
Collapse
|
98
|
Abstract
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide. However, the mechanisms by which clots are formed in the deep veins have not been determined. Tissue factor (TF) is the primary initiator of the coagulation cascade and is essential for hemostasis. Under pathological conditions, TF is released into the circulation on small-membrane vesicles termed microparticles (MPs). Recent studies suggest that elevated levels of MP TF may trigger thrombosis. This review provides an overview of the role of TF in VTE.
Collapse
Affiliation(s)
- David A Manly
- Brody School of Medicine, East Caroline University, Greenville, North Carolina 27834, USA
| | | | | |
Collapse
|
99
|
Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia. Blood 2011; 118:3359-66. [PMID: 21705500 DOI: 10.1182/blood-2011-02-337337] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Essential thrombocythemia (ET) and polycythemia vera (PV) are characterized by persistent platelet activation. The mechanisms involved in their clearance are poorly characterized. In the present study, we report that leukocytes were actively involved in platelet disposal in 51 patients with ET and 30 with PV, but not in 70 age- and sex-matched controls. The fraction of circulating neutrophils and monocytes that had phagocytosed platelets, as assessed by flow cytometry, was significantly higher in patients with PV or ET, independently of hydroxyurea treatment, than in controls. Platelet phagocytosis by circulating leukocytes was confirmed by confocal and electron microscopy. The lack of effect of hydroxyurea, which disrupts the P-selectin/P-selectin glycoprotein ligand 1 (PSGL-1) interaction, suggests a P-selectin-independent mechanism. This hypothesis was confirmed in an ad hoc animal model based on the in vivo injection of activated platelets from P-selectin(+/+) and P-selectin(-/-) mice. P-selectin expression was associated with an earlier and effective clearance of platelets by neutrophils. A second delayed, P-selectin-independent phase actively involved monocytes. Our results suggest that phagocytic clearance of platelets by leukocytes occurs in PV and ET, possibly involving P-selectin-dependent and -independent pathways, thus representing a novel mechanism to remove activated platelets from the circulation.
Collapse
|
100
|
Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011; 118:1952-61. [PMID: 21673343 DOI: 10.1182/blood-2011-03-343061] [Citation(s) in RCA: 608] [Impact Index Per Article: 46.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
The release of histones from dying cells is associated with microvascular thrombosis and, because histones activate platelets, this could represent a possible pathogenic mechanism. In the present study, we assessed the influence of histones on the procoagulant potential of human platelets in platelet-rich plasma (PRP) and in purified systems. Histones dose-dependently enhanced thrombin generation in PRP in the absence of any trigger, as evaluated by calibrated automated thrombinography regardless of whether the contact phase was inhibited. Activation of coagulation required the presence of fully activatable platelets and was not ascribable to platelet tissue factor, whereas targeting polyphosphate with phosphatase reduced thrombin generation even when factor XII (FXII) was blocked or absent. In the presence of histones, purified polyphosphate was able to induce thrombin generation in plasma independently of FXII. In purified systems, histones induced platelet aggregation; P-selectin, phosphatidylserine, and FV/Va expression; and prothrombinase activity. Blocking platelet TLR2 and TLR4 with mAbs reduced the percentage of activated platelets and lowered the amount of thrombin generated in PRP. These data show that histone-activated platelets possess a procoagulant phenotype that drives plasma thrombin generation and suggest that TLR2 and TLR4 mediate the activation process.
Collapse
|